Advertisement

Annals of Surgical Oncology

, Volume 18, Issue 7, pp 1891–1898 | Cite as

OSNA-Based Novel Molecular Testing for Lymph Node Metastases in Colorectal Cancer Patients: Results from a Multicenter Clinical Performance Study in Japan

  • Hirofumi YamamotoEmail author
  • Mitsugu Sekimoto
  • Masatoshi Oya
  • Noriko Yamamoto
  • Fumio Konishi
  • Junichi Sasaki
  • Shigeki Yamada
  • Kiyomi Taniyama
  • Harumi Tominaga
  • Masahiko Tsujimoto
  • Hiroki Akamatsu
  • Akio Yanagisawa
  • Chouhei Sakakura
  • Yo Kato
  • Nariaki Matsuura
Colorectal Cancer

Abstract

Background

Lymph node (LN) metastasis in colorectal cancer (CRC) is a critical factor in making accurate prognoses and therapeutic decisions. This study evaluated the clinical performance of the one-step nucleic acid amplification (OSNA) assay in accurately diagnosing LN metastases in CRC patients through the specific detection of cytokeratin 19 mRNA levels in LNs.

Methods

The OSNA assay was performed on 121 LNs dissected from early-stage CRC patients (pStage 0 or I) or from patients with benign colorectal disease (study 1). Separately, 385 LNs were dissected from 85 CRC patients (any stage); the OSNA assay was performed on half of each LN, and the results were compared with histopathological examination in 2-mm intervals of the other LN half (study 2).

Results

In study 1, all 121 histopathologically negative LNs were also negative by the OSNA assay (concordance rate for metastasis negative: 1.0, 95% confidence interval [95% CI]: 0.976–1.0). In study 2, the concordance rate between the OSNA assay and the 2-mm-interval histopathological examination was 0.971 (95% CI: 0.950–0.984), with a sensitivity of 0.952 (95% CI: 0.881–0.987) and a specificity of 0.977 (95% CI: 0.953–0.991).

Conclusions

The OSNA assay provided a judgment performance equivalent to a 2-mm-interval histopathological examination, a more detailed assay than the common pathological examination. Therefore, the OSNA assay is considered a new molecular examination method for the diagnosis of LN metastases in CRC patients in clinical settings.

Keywords

Histopathological Examination CK19 mRNA Detect Lymph Node Metastasis Lymph Node Block OSNA Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

We thank the staff of the clinical and pathologic laboratories at the participating institutes and the Sysmex Corporation (Reiko Watanabe, Hayato Niiro) for technical support. Grant support: Sysmex Corporation. Note: Sysmex Corporation contributed to providing the RD-100i system, funding of laboratory consumables for the OSNA assay, sample collection, and data analysis, but had no role in data interpretation or writing of this report.

References

  1. 1.
    Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, et al. A Multivariate analysis of clinical and pathologic variables in prognosis after resection of large bowel cancer. Br J Surg. 1985;72:698–702.PubMedCrossRefGoogle Scholar
  2. 2.
    Moertel CG. Chemotherapy for colorectal cancer. New Engl J Med. 1994;330:1136–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Dukes CE, Bussey HJ. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958;12:309–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Gennari C, Doci R, Rossetti C. Prognostic factors in colorectal cancer. Hepatogastroenterology. 2000;47:310–4.PubMedGoogle Scholar
  5. 5.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with new American Joint Committee on Cancer Sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Burke HB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst. 2004;96:1408–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Feezor RJ, Copeland EM III, Hochwald SN. Significance of micrometastases in colorectal cancer. Ann Surg Oncol. 2002;9:944–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol. 2006;13:1386–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Takayama O, et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol. 2002;20:4232–41.PubMedCrossRefGoogle Scholar
  10. 10.
    Bilchik AJ, Hoon DS, Saha S, Turner RR, Wiese D, DiNome M, et al. Prognostic impact of micrometastases in colon cancer. Ann Surg. 2007;246:568–75.PubMedCrossRefGoogle Scholar
  11. 11.
    Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13:4807–16.PubMedCrossRefGoogle Scholar
  12. 12.
    Visser M, Jiwa M, Horstman A, Brink AA, Pol RP, van Diest P, et al. Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer. 2008;122:2562–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Schem C, Maass N, Bauerschlag DO, Carstensen MH, Löning T, Roder C, et al. One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch. 2009;454:203–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Tamaki Y, Akiyama M, Iwase T, Kaneko T, Tsuda H, Sato K, et al. Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res. 2009;15:2879–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Taniyama K, Motoshita J, Sakane J, Makita K, Akai Y, Daito M, et al. Combination analysis of a whole lymph node by one-step nucleic acid amplification and histology for intraoperative detection of micrometastasis. Pathobiology. 2006;73:183–91.PubMedCrossRefGoogle Scholar
  16. 16.
    Croner RS, Schellerer V, Demund H, Schildberg C, Papadopulos T, Naschberger E, et al. One step nucleic acid amplification (OSNA) a new method for lymph node staging in colorectal carcinomas. J Transl Med. 2010;8:83.PubMedCrossRefGoogle Scholar
  17. 17.
    Zippelius A, Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci. 2000;906:110–23.CrossRefGoogle Scholar
  18. 18.
    Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Cutsem E, Oliveira J. Colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2008;19:ii29–30.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Hirofumi Yamamoto
    • 1
    Email author
  • Mitsugu Sekimoto
    • 1
  • Masatoshi Oya
    • 2
  • Noriko Yamamoto
    • 3
  • Fumio Konishi
    • 4
  • Junichi Sasaki
    • 4
  • Shigeki Yamada
    • 5
  • Kiyomi Taniyama
    • 6
  • Harumi Tominaga
    • 7
  • Masahiko Tsujimoto
    • 8
  • Hiroki Akamatsu
    • 9
  • Akio Yanagisawa
    • 10
  • Chouhei Sakakura
    • 11
  • Yo Kato
    • 3
  • Nariaki Matsuura
    • 12
  1. 1.Department of Surgery, Gastroenterological Surgery, Graduate School of MedicineOsaka UniversityOsakaJapan
  2. 2.Gastroenterological Center, Department of Gastroenterological SurgeryCancer Institute Ariake HospitalTokyoJapan
  3. 3.Department of PathologyThe Cancer Institute of the Japanese Foundation for Cancer ResearchTokyoJapan
  4. 4.Department of Surgery, Saitama Medical CenterJichi Medical UniversitySaitamaJapan
  5. 5.Department of Pathology, Saitama Medical CenterJichi Medical UniversitySaitamaJapan
  6. 6.Institute for Clinical ResearchNational Hospital Organization Kure Medical Center and Chugoku Cancer CenterHiroshimaJapan
  7. 7.Department of SurgeryNational Hospital Organization Kure Medical Center and Chugoku Cancer CenterHiroshimaJapan
  8. 8.Department of PathologyOsaka Police HospitalOsakaJapan
  9. 9.Department of SurgeryOsaka Police HospitalOsakaJapan
  10. 10.Department of Surgical PathologyKyoto Prefectural University of MedicineKyotoJapan
  11. 11.Department of SurgeryKyoto Prefectural University of MedicineKyotoJapan
  12. 12.Department of Molecular Pathology, Graduate School of Medicine and Health ScienceOsaka UniversityOsakaJapan

Personalised recommendations